Solid dispersion of alectinib HCl: preclinical evaluation for improving bioavailability and establishing an IVIVC model

A stable ASD formulation of ALB-HCl was successfully developed with improved bioavailability. Developing an IVIVC model can act as a surrogate to predict in-vivo performance. The selection of formulation components in ASD shall be rationalized for bioavailability and stability before clinical evaluation.